# SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Study · id `cardio:ct-nct06155604` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06155604](<https://clinicaltrials.gov/study/NCT06155604>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06155604

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06155604. Randomized; double masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06155604, source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)
- Started: 2023-01-04 (actual) (ClinicalTrials.gov record NCT06155604, source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06155604, source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06155604, source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT06155604, source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06155604-2024-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
- Condition: Lupus Nephritis
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Drug): Standard maintenance therapy
- Lead sponsor: The University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: The University of Hong Kong (`cardio:org-the-university-of-hong-kong`)

## Provenance

Content hash: 00a12c2c1aa23402ace5efdf289f9e6ea84cee3dc8aca1d8fa5cdd0574342f49
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
